Empyrean Capital Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marathon Petroleum
MPC
|
+$77M |
| 2 |
FTAI Aviation
FTAI
|
+$65.5M |
| 3 |
UnitedHealth
UNH
|
+$61.3M |
| 4 |
Cardinal Health
CAH
|
+$48.3M |
| 5 |
CVS Health
CVS
|
+$38.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dominion Energy
D
|
+$84.7M |
| 2 |
DFS
Discover Financial Services
DFS
|
+$75.9M |
| 3 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
+$66M |
| 4 |
AES
AES
|
+$48.3M |
| 5 |
KBR
KBR
|
+$37.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 39.72% |
| 2 | Energy | 16.94% |
| 3 | Industrials | 9.76% |
| 4 | Healthcare | 9.22% |
| 5 | Financials | 6.29% |
Similar funds
Empyrean Capital Partners's Q1 2025 Portfolio in Review
As of Q1 2025, Empyrean Capital Partners held 81 positions worth $2.82B, up 29% from $2.19B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Empyrean Capital Partners withdrew a net $333M in Q1 2025, closing 22 positions and reducing 5 holdings. Its most notable exit was Dominion Energy, an estimated $84.7M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 40% of assets, up from 19% a quarter earlier, followed by Energy and Industrials.
Against the trend, Empyrean Capital Partners opened a new position in Marathon Petroleum worth $75.8M.
- Empyrean Capital Partners's largest Q1 2025 buy was Marathon Petroleum: 520,500 shares worth $75.8M.
- Empyrean Capital Partners added most to CVS Health in Q1 2025, an estimated $38.4M increase.
- Empyrean Capital Partners's biggest Q1 2025 reduction was Discover Financial Services, cutting an estimated $75.9M.
- Empyrean Capital Partners fully exited Dominion Energy in Q1 2025, selling an estimated $84.7M.
- Empyrean Capital Partners's ten largest holdings make up 63% of its $2.82B portfolio in Q1 2025.
- Empyrean Capital Partners opened 13 new positions and closed 22 in Q1 2025.
- Empyrean Capital Partners's portfolio value rose 29% quarter-over-quarter to $2.82B.
Based on Empyrean Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.